Idioma:

A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients

Ohe, Y. ; Niho, S. ; Kakinuma, R. ; Kubota, K. ; Ohmatsu, H. ; Goto, K. ; Nokihara, H. ; Kunitoh, H. ; Saijo, N. ; Aono, H. ; Watanabe, K. ; Tango, M. ; Yokoyama, A. ; Nishiwaki, Y.

Annals of oncology, 2004-01, Vol.15 (1), p.45-50 [Periódico revisado por pares]

Oxford: Oxford University Press

Texto completo disponível

Citações Citado por

Enviar para

Título:
A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients
Autor: Ohe, Y. ; Niho, S. ; Kakinuma, R. ; Kubota, K. ; Ohmatsu, H. ; Goto, K. ; Nokihara, H. ; Kunitoh, H. ; Saijo, N. ; Aono, H. ; Watanabe, K. ; Tango, M. ; Yokoyama, A. ; Nishiwaki, Y.
Assuntos: Aged ; Aged, 80 and over ; Antineoplastic agents ; Antineoplastic Agents, Phytogenic - administration & dosage ; Antineoplastic Agents, Phytogenic - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - mortality ; cisplatin ; Cisplatin - administration & dosage ; Cisplatin - adverse effects ; Docetaxel ; Drug Administration Schedule ; elderly patients ; Female ; Humans ; Infusions, Intravenous ; Lung Neoplasms - drug therapy ; Lung Neoplasms - mortality ; Male ; Medical sciences ; non-small-cell lung cancer ; Pharmacology. Drug treatments ; Safety ; Survival Analysis ; Taxoids - administration & dosage ; Taxoids - adverse effects ; Treatment Outcome ; Tumors ; weekly administration
É parte de: Annals of oncology, 2004-01, Vol.15 (1), p.45-50
Notas: ark:/67375/HXZ-48ZKFZL0-G
local:mdh015
istex:601BC9DB78B83FD6CA69966BBA4B1A1B87162D13
Received 20 April 2003; revised 17 August 2003; accepted 28 August 2003
Descrição: Background: To evaluate the efficacy and safety of treatments for advanced non-small-cell lung cancer in elderly patients aged 75 years or older, we conducted a phase II study of cisplatin and docetaxel administered in three consecutive weekly infusions. Patients and methods: The eligibility criteria for the study included the presence of chemotherapy-naive advanced non-small-cell lung cancer, age ≥75 years, Eastern Cooperative Oncology Group performance status of 0 or 1, a measurable lesion, adequate organ functions and signed informed consent. The chemotherapy regimen consisted of cisplatin (25 mg/m2) and docetaxel (20 mg/m2) on days 1, 8 and 15 every 4 weeks. Results: Between February 2000 and March 2002, 34 elderly patients with non-small-cell lung cancer were enrolled in the study and 33 patients were treated. Two complete responses and 15 partial responses were obtained for an objective response rate of 52% in 33 treated patients. The median survival period was 15.8 months, and the 1-year survival rate was 64%. Toxicities were mild with no grade 4 toxicities. Only grade 3 leukopenia (6%), neutropenia (12%), anemia (3%), hyponatremia (3%) and nausea/vomiting (3%) were observed. Conclusion: Cisplatin and docetaxel administered in three consecutive weekly infusions was safe and effective for the treatment of elderly patients with chemotherapy-naive non-small-cell lung cancer.
Editor: Oxford: Oxford University Press
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients

Ohe, Y. ; Niho, S. ; Kakinuma, R. ; Kubota, K. ; Ohmatsu, H. ; Goto, K. ; Nokihara, H. ; Kunitoh, H. ; Saijo, N. ; Aono, H. ; Watanabe, K. ; Tango, M. ; Yokoyama, A. ; Nishiwaki, Y.

Oxford: Oxford University Press

Buscando em bases de dados remotas. Favor aguardar.